Meeting
2023 ASCO Annual Meeting
Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Authors
Tara L. Lin
Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS
Tara L. Lin , Robyn Wood , Tammy Ham , Taegen Sullivan , Prasad Dandawate , Shrikant Anant , Marianne T Santaguida , Paul Toren , Roy A. Jensen , John A. Taylor III, Michael Jay Baltezor , Michael Dalton , Fred Meyer , John McBride , Jay Nicholas Umbreit , William McCulloch , Kathryn Vanderlaag , Joseph Wagner , Scott James Weir , B. Douglas Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04956042
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7078)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7078
Abstract #
TPS7078
Poster Bd #
205b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
First Author: Tara L. Lin
Poster
2013 ASCO Annual Meeting
A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.
First Author: Alan Hilary Calvert
Poster
2020 Genitourinary Cancers Symposium
Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients.
First Author: John Arthur Taylor III
Poster
2019 ASCO Annual Meeting
A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
First Author: Emiliano Calvo